Treatment of Primary Autoimmune Cerebellar Ataxia with Mycophenolate View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2020-06-10

AUTHORS

M. Hadjivassiliou, R. A. Grunewald, P. D. Shanmugarajah, P. G. Sarrigiannis, P. Zis, V. Skarlatou, N. Hoggard

ABSTRACT

Immune-mediated ataxias account for a substantial number of sporadic otherwise idiopathic ataxias. Despite some well-characterised entities such as paraneoplastic cerebellar degeneration where diagnostic markers exist, the majority of immune ataxias remained undiagnosed and untreated. We present here our experience in the treatment of suspected primary autoimmune cerebellar ataxia (PACA) using mycophenolate. All patients reported attend the Sheffield Ataxia Centre on a regular basis and had undergone extensive investigations, including genetic testing using next-generation sequencing, with other causes of ataxia excluded. The diagnosis of PACA was strongly suspected based on investigations, pattern of disease progression, and cerebellar involvement. Patients were treated with mycophenolate and monitored using MR spectroscopy of the cerebellar vermis. Thirty patients with PACA are reported here. Of these, 22 received mycophenolate (group 1). The remaining 8 were not on treatment (group 2-control group). Out of the 22 treated patients, 4 underwent serial MR spectroscopy prior to starting treatment and thus were used as controls making the total number of patients in the control group 12. The mean change of the MRS within the vermis (NAA/Cr area ratio) in the treatment group was + 0.144 ± 0.09 (improved) and in the untreated group − 0.155 ± 0.06 (deteriorated). The difference was significant. We also demonstrated a strong correlation between the spectroscopy and the SARA score. We have demonstrated the effectiveness of mycophenolate in the treatment of PACA. The results suggest that immune-mediated ataxias are potentially treatable, and that there is a need for early diagnosis to prevent permanent neurological deficit. The recently published diagnostic criteria for PACA would hopefully aid the diagnosis and treatment of this entity. More... »

PAGES

680-684

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12311-020-01152-4

DOI

http://dx.doi.org/10.1007/s12311-020-01152-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1128395600

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/32524518


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ataxia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cerebellar Ataxia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cerebellum", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Magnetic Resonance Spectroscopy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mycophenolic Acid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Spinocerebellar Ataxias", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Academic Department of Neurosciences, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK", 
          "id": "http://www.grid.ac/institutes/grid.31410.37", 
          "name": [
            "Academic Department of Neurosciences, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hadjivassiliou", 
        "givenName": "M.", 
        "id": "sg:person.01354423242.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354423242.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Academic Department of Neurosciences, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK", 
          "id": "http://www.grid.ac/institutes/grid.31410.37", 
          "name": [
            "Academic Department of Neurosciences, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Grunewald", 
        "givenName": "R. A.", 
        "id": "sg:person.01130424341.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130424341.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Academic Department of Neurosciences, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK", 
          "id": "http://www.grid.ac/institutes/grid.31410.37", 
          "name": [
            "Academic Department of Neurosciences, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shanmugarajah", 
        "givenName": "P. D.", 
        "id": "sg:person.01273701327.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273701327.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Academic Department of Neurosciences, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK", 
          "id": "http://www.grid.ac/institutes/grid.31410.37", 
          "name": [
            "Academic Department of Neurosciences, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sarrigiannis", 
        "givenName": "P. G.", 
        "id": "sg:person.01132771412.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132771412.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Academic Department of Neurosciences, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK", 
          "id": "http://www.grid.ac/institutes/grid.31410.37", 
          "name": [
            "Academic Department of Neurosciences, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zis", 
        "givenName": "P.", 
        "id": "sg:person.0735760516.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0735760516.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Neurology, Evaggelismos General Hospital, Athens, Greece", 
          "id": "http://www.grid.ac/institutes/grid.414655.7", 
          "name": [
            "Department of Neurology, Evaggelismos General Hospital, Athens, Greece"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Skarlatou", 
        "givenName": "V.", 
        "id": "sg:person.013074107730.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013074107730.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "IICD insigneo, University of Sheffield, Sheffield, UK", 
          "id": "http://www.grid.ac/institutes/grid.11835.3e", 
          "name": [
            "IICD insigneo, University of Sheffield, Sheffield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hoggard", 
        "givenName": "N.", 
        "id": "sg:person.0610025364.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610025364.39"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s12311-019-01048-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1117009020", 
          "https://doi.org/10.1007/s12311-019-01048-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s40673-015-0021-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015787585", 
          "https://doi.org/10.1186/s40673-015-0021-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s40673-015-0034-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024291047", 
          "https://doi.org/10.1186/s40673-015-0034-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12311-020-01132-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1126922911", 
          "https://doi.org/10.1007/s12311-020-01132-8"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-06-10", 
    "datePublishedReg": "2020-06-10", 
    "description": "Immune-mediated ataxias account for a substantial number of sporadic otherwise idiopathic ataxias. Despite some well-characterised entities such as paraneoplastic cerebellar degeneration where diagnostic markers exist, the majority of immune ataxias remained undiagnosed and untreated. We present here our experience in the treatment of suspected primary autoimmune cerebellar ataxia (PACA) using mycophenolate. All patients reported attend the Sheffield Ataxia Centre on a regular basis and had undergone extensive investigations, including genetic testing using next-generation sequencing, with other causes of ataxia excluded. The diagnosis of PACA was strongly suspected based on investigations, pattern of disease progression, and cerebellar involvement. Patients were treated with mycophenolate and monitored using MR spectroscopy of the cerebellar vermis. Thirty patients with PACA are reported here. Of these, 22 received mycophenolate (group 1). The remaining 8 were not on treatment (group 2-control group). Out of the 22 treated patients, 4 underwent serial MR spectroscopy prior to starting treatment and thus were used as controls making the total number of patients in the control group 12. The mean change of the MRS within the vermis (NAA/Cr area ratio) in the treatment group was +\u20090.144\u2009\u00b1\u20090.09 (improved) and in the untreated group \u2212\u20090.155\u2009\u00b1\u20090.06 (deteriorated). The difference was significant. We also demonstrated a strong correlation between the spectroscopy and the SARA score. We have demonstrated the effectiveness of mycophenolate in the treatment of PACA. The results suggest that immune-mediated ataxias are potentially treatable, and that there is a need for early diagnosis to prevent permanent neurological deficit. The recently published diagnostic criteria for PACA would hopefully aid the diagnosis and treatment of this entity.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12311-020-01152-4", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1028483", 
        "issn": [
          "1473-4222", 
          "1473-4230"
        ], 
        "name": "The Cerebellum", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "keywords": [
      "primary autoimmune cerebellar ataxia", 
      "autoimmune cerebellar ataxia", 
      "cerebellar ataxia", 
      "MR spectroscopy", 
      "Sheffield Ataxia Centre", 
      "control group 12", 
      "permanent neurological deficits", 
      "paraneoplastic cerebellar degeneration", 
      "causes of ataxia", 
      "immune ataxias", 
      "neurological deficits", 
      "disease progression", 
      "idiopathic ataxia", 
      "mean change", 
      "untreated group", 
      "mycophenolate", 
      "early diagnosis", 
      "SARA scores", 
      "treatment groups", 
      "cerebellar vermis", 
      "diagnostic criteria", 
      "cerebellar degeneration", 
      "patients", 
      "cerebellar involvement", 
      "genetic testing", 
      "diagnostic marker", 
      "ataxia", 
      "next-generation sequencing", 
      "diagnosis", 
      "treatment", 
      "vermis", 
      "substantial number", 
      "group 12", 
      "total number", 
      "regular basis", 
      "group", 
      "extensive investigation", 
      "degeneration", 
      "Immune", 
      "strong correlation", 
      "progression", 
      "MRS", 
      "scores", 
      "markers", 
      "cause", 
      "deficits", 
      "entities", 
      "involvement", 
      "majority", 
      "differences", 
      "testing", 
      "sequencing", 
      "control", 
      "criteria", 
      "center", 
      "number", 
      "correlation", 
      "investigation", 
      "experience", 
      "changes", 
      "need", 
      "patterns", 
      "effectiveness", 
      "results", 
      "basis", 
      "spectroscopy"
    ], 
    "name": "Treatment of Primary Autoimmune Cerebellar Ataxia with Mycophenolate", 
    "pagination": "680-684", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1128395600"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12311-020-01152-4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "32524518"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12311-020-01152-4", 
      "https://app.dimensions.ai/details/publication/pub.1128395600"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T21:05", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_849.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12311-020-01152-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12311-020-01152-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12311-020-01152-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12311-020-01152-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12311-020-01152-4'


 

This table displays all metadata directly associated to this object as RDF triples.

255 TRIPLES      21 PREDICATES      111 URIs      99 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12311-020-01152-4 schema:about N2429e5912fb9439fb246f69f4b4bef6c
2 N3519510b6edd43f9b81bc6886c1c29bb
3 N3e03f1f9fd7741ea8d22d7164397d111
4 N7588e9d0b6cf4938935579a020ff95ba
5 N7a5a74b7016548c495a5babc17f068e1
6 N9677f50dc2af42d284ca356fff886150
7 Na2cebbb222f64f83b9340393356ba4fb
8 Naa960fb5a88741a08453d27ccf2df47a
9 Nacf037863b0b42109662baa13e7f1915
10 Nb158564ecbcb4b44b3c283e975a35444
11 Ncf7b874ec476466eb4d1da33ccf7d8d9
12 Nd2dc93d489cc488db193cbdb198ab88b
13 Nd43ce1a4e2f24e81a0e1485f7081ab18
14 Nd7c5c22e8edf4656b0479979681d0c65
15 Nf1cea2a87e14404cbe63eb4d19572773
16 Nf5df200d2d784b028f718a5353b8f2e5
17 anzsrc-for:11
18 anzsrc-for:1103
19 schema:author Ne61b9a4f72fc4979aa1a0703def72405
20 schema:citation sg:pub.10.1007/s12311-019-01048-y
21 sg:pub.10.1007/s12311-020-01132-8
22 sg:pub.10.1186/s40673-015-0021-3
23 sg:pub.10.1186/s40673-015-0034-y
24 schema:datePublished 2020-06-10
25 schema:datePublishedReg 2020-06-10
26 schema:description Immune-mediated ataxias account for a substantial number of sporadic otherwise idiopathic ataxias. Despite some well-characterised entities such as paraneoplastic cerebellar degeneration where diagnostic markers exist, the majority of immune ataxias remained undiagnosed and untreated. We present here our experience in the treatment of suspected primary autoimmune cerebellar ataxia (PACA) using mycophenolate. All patients reported attend the Sheffield Ataxia Centre on a regular basis and had undergone extensive investigations, including genetic testing using next-generation sequencing, with other causes of ataxia excluded. The diagnosis of PACA was strongly suspected based on investigations, pattern of disease progression, and cerebellar involvement. Patients were treated with mycophenolate and monitored using MR spectroscopy of the cerebellar vermis. Thirty patients with PACA are reported here. Of these, 22 received mycophenolate (group 1). The remaining 8 were not on treatment (group 2-control group). Out of the 22 treated patients, 4 underwent serial MR spectroscopy prior to starting treatment and thus were used as controls making the total number of patients in the control group 12. The mean change of the MRS within the vermis (NAA/Cr area ratio) in the treatment group was + 0.144 ± 0.09 (improved) and in the untreated group − 0.155 ± 0.06 (deteriorated). The difference was significant. We also demonstrated a strong correlation between the spectroscopy and the SARA score. We have demonstrated the effectiveness of mycophenolate in the treatment of PACA. The results suggest that immune-mediated ataxias are potentially treatable, and that there is a need for early diagnosis to prevent permanent neurological deficit. The recently published diagnostic criteria for PACA would hopefully aid the diagnosis and treatment of this entity.
27 schema:genre article
28 schema:isAccessibleForFree true
29 schema:isPartOf N8398a88cd9b4457190b1375d86e5cde0
30 N8ad4b48eb03e4efa844ece8c8383d6b1
31 sg:journal.1028483
32 schema:keywords Immune
33 MR spectroscopy
34 MRS
35 SARA scores
36 Sheffield Ataxia Centre
37 ataxia
38 autoimmune cerebellar ataxia
39 basis
40 cause
41 causes of ataxia
42 center
43 cerebellar ataxia
44 cerebellar degeneration
45 cerebellar involvement
46 cerebellar vermis
47 changes
48 control
49 control group 12
50 correlation
51 criteria
52 deficits
53 degeneration
54 diagnosis
55 diagnostic criteria
56 diagnostic marker
57 differences
58 disease progression
59 early diagnosis
60 effectiveness
61 entities
62 experience
63 extensive investigation
64 genetic testing
65 group
66 group 12
67 idiopathic ataxia
68 immune ataxias
69 investigation
70 involvement
71 majority
72 markers
73 mean change
74 mycophenolate
75 need
76 neurological deficits
77 next-generation sequencing
78 number
79 paraneoplastic cerebellar degeneration
80 patients
81 patterns
82 permanent neurological deficits
83 primary autoimmune cerebellar ataxia
84 progression
85 regular basis
86 results
87 scores
88 sequencing
89 spectroscopy
90 strong correlation
91 substantial number
92 testing
93 total number
94 treatment
95 treatment groups
96 untreated group
97 vermis
98 schema:name Treatment of Primary Autoimmune Cerebellar Ataxia with Mycophenolate
99 schema:pagination 680-684
100 schema:productId N3a59605446e047e1b42a7b2673b2fc16
101 N3ec0b89a4ff44035a7100c7bbe708dd1
102 Nc731f7e84bde43e58cda4594f4024c4b
103 schema:sameAs https://app.dimensions.ai/details/publication/pub.1128395600
104 https://doi.org/10.1007/s12311-020-01152-4
105 schema:sdDatePublished 2022-11-24T21:05
106 schema:sdLicense https://scigraph.springernature.com/explorer/license/
107 schema:sdPublisher Nbd4f96295b3d44e3b406def9ecfe8ef5
108 schema:url https://doi.org/10.1007/s12311-020-01152-4
109 sgo:license sg:explorer/license/
110 sgo:sdDataset articles
111 rdf:type schema:ScholarlyArticle
112 N0b8f3bad602a46d290f66a4d46e8d5ef rdf:first sg:person.01273701327.13
113 rdf:rest Nd9b78509808a4350bcadda9c1c4338d0
114 N2429e5912fb9439fb246f69f4b4bef6c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Female
116 rdf:type schema:DefinedTerm
117 N3519510b6edd43f9b81bc6886c1c29bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Aged, 80 and over
119 rdf:type schema:DefinedTerm
120 N3a59605446e047e1b42a7b2673b2fc16 schema:name dimensions_id
121 schema:value pub.1128395600
122 rdf:type schema:PropertyValue
123 N3e03f1f9fd7741ea8d22d7164397d111 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Adolescent
125 rdf:type schema:DefinedTerm
126 N3ec0b89a4ff44035a7100c7bbe708dd1 schema:name pubmed_id
127 schema:value 32524518
128 rdf:type schema:PropertyValue
129 N490017b6f8f1403e8b33d17e69b5a476 rdf:first sg:person.0735760516.32
130 rdf:rest Nfc392b8db434407ba416307a6a3880a3
131 N7588e9d0b6cf4938935579a020ff95ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Young Adult
133 rdf:type schema:DefinedTerm
134 N7a5a74b7016548c495a5babc17f068e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Middle Aged
136 rdf:type schema:DefinedTerm
137 N8398a88cd9b4457190b1375d86e5cde0 schema:issueNumber 5
138 rdf:type schema:PublicationIssue
139 N8ad4b48eb03e4efa844ece8c8383d6b1 schema:volumeNumber 19
140 rdf:type schema:PublicationVolume
141 N9677f50dc2af42d284ca356fff886150 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Aged
143 rdf:type schema:DefinedTerm
144 Na2cebbb222f64f83b9340393356ba4fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Humans
146 rdf:type schema:DefinedTerm
147 Naa960fb5a88741a08453d27ccf2df47a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Ataxia
149 rdf:type schema:DefinedTerm
150 Nacf037863b0b42109662baa13e7f1915 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Magnetic Resonance Spectroscopy
152 rdf:type schema:DefinedTerm
153 Nb158564ecbcb4b44b3c283e975a35444 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Mycophenolic Acid
155 rdf:type schema:DefinedTerm
156 Nb3f5abacc94c4d8dbcee52a815ebc26f rdf:first sg:person.0610025364.39
157 rdf:rest rdf:nil
158 Nbd4f96295b3d44e3b406def9ecfe8ef5 schema:name Springer Nature - SN SciGraph project
159 rdf:type schema:Organization
160 Nc731f7e84bde43e58cda4594f4024c4b schema:name doi
161 schema:value 10.1007/s12311-020-01152-4
162 rdf:type schema:PropertyValue
163 Ncf7b874ec476466eb4d1da33ccf7d8d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Cerebellar Ataxia
165 rdf:type schema:DefinedTerm
166 Nd2dc93d489cc488db193cbdb198ab88b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Male
168 rdf:type schema:DefinedTerm
169 Nd43ce1a4e2f24e81a0e1485f7081ab18 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Disease Progression
171 rdf:type schema:DefinedTerm
172 Nd7c5c22e8edf4656b0479979681d0c65 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Spinocerebellar Ataxias
174 rdf:type schema:DefinedTerm
175 Nd9b78509808a4350bcadda9c1c4338d0 rdf:first sg:person.01132771412.11
176 rdf:rest N490017b6f8f1403e8b33d17e69b5a476
177 Ne61b9a4f72fc4979aa1a0703def72405 rdf:first sg:person.01354423242.83
178 rdf:rest Nf7f0a9d9fdee479ba0cf6939151406ee
179 Nf1cea2a87e14404cbe63eb4d19572773 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Cerebellum
181 rdf:type schema:DefinedTerm
182 Nf5df200d2d784b028f718a5353b8f2e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Adult
184 rdf:type schema:DefinedTerm
185 Nf7f0a9d9fdee479ba0cf6939151406ee rdf:first sg:person.01130424341.44
186 rdf:rest N0b8f3bad602a46d290f66a4d46e8d5ef
187 Nfc392b8db434407ba416307a6a3880a3 rdf:first sg:person.013074107730.04
188 rdf:rest Nb3f5abacc94c4d8dbcee52a815ebc26f
189 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
190 schema:name Medical and Health Sciences
191 rdf:type schema:DefinedTerm
192 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
193 schema:name Clinical Sciences
194 rdf:type schema:DefinedTerm
195 sg:journal.1028483 schema:issn 1473-4222
196 1473-4230
197 schema:name The Cerebellum
198 schema:publisher Springer Nature
199 rdf:type schema:Periodical
200 sg:person.01130424341.44 schema:affiliation grid-institutes:grid.31410.37
201 schema:familyName Grunewald
202 schema:givenName R. A.
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130424341.44
204 rdf:type schema:Person
205 sg:person.01132771412.11 schema:affiliation grid-institutes:grid.31410.37
206 schema:familyName Sarrigiannis
207 schema:givenName P. G.
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132771412.11
209 rdf:type schema:Person
210 sg:person.01273701327.13 schema:affiliation grid-institutes:grid.31410.37
211 schema:familyName Shanmugarajah
212 schema:givenName P. D.
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273701327.13
214 rdf:type schema:Person
215 sg:person.013074107730.04 schema:affiliation grid-institutes:grid.414655.7
216 schema:familyName Skarlatou
217 schema:givenName V.
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013074107730.04
219 rdf:type schema:Person
220 sg:person.01354423242.83 schema:affiliation grid-institutes:grid.31410.37
221 schema:familyName Hadjivassiliou
222 schema:givenName M.
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354423242.83
224 rdf:type schema:Person
225 sg:person.0610025364.39 schema:affiliation grid-institutes:grid.11835.3e
226 schema:familyName Hoggard
227 schema:givenName N.
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610025364.39
229 rdf:type schema:Person
230 sg:person.0735760516.32 schema:affiliation grid-institutes:grid.31410.37
231 schema:familyName Zis
232 schema:givenName P.
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0735760516.32
234 rdf:type schema:Person
235 sg:pub.10.1007/s12311-019-01048-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1117009020
236 https://doi.org/10.1007/s12311-019-01048-y
237 rdf:type schema:CreativeWork
238 sg:pub.10.1007/s12311-020-01132-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1126922911
239 https://doi.org/10.1007/s12311-020-01132-8
240 rdf:type schema:CreativeWork
241 sg:pub.10.1186/s40673-015-0021-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015787585
242 https://doi.org/10.1186/s40673-015-0021-3
243 rdf:type schema:CreativeWork
244 sg:pub.10.1186/s40673-015-0034-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1024291047
245 https://doi.org/10.1186/s40673-015-0034-y
246 rdf:type schema:CreativeWork
247 grid-institutes:grid.11835.3e schema:alternateName IICD insigneo, University of Sheffield, Sheffield, UK
248 schema:name IICD insigneo, University of Sheffield, Sheffield, UK
249 rdf:type schema:Organization
250 grid-institutes:grid.31410.37 schema:alternateName Academic Department of Neurosciences, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK
251 schema:name Academic Department of Neurosciences, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK
252 rdf:type schema:Organization
253 grid-institutes:grid.414655.7 schema:alternateName Department of Neurology, Evaggelismos General Hospital, Athens, Greece
254 schema:name Department of Neurology, Evaggelismos General Hospital, Athens, Greece
255 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...